OptimizeRx Corporation (NASDAQ:OPRX) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Miriam Paramore - President Conference Call Participants Andrew D'Silva - B. Riley FBR, Inc. Ryan Daniels - William Blair & Company, L.L.C. Richard Baldry - ROTH Capital Partners, LLC Eric Martinuzzi - Lake Street Capital Markets, LLC Josh Goldberg - G2 Investment Partne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

NASDAQ:OPRX A Digital Health Platform Corporate Presentation Physician Communications Patient Engagement Adherence September 2020 © Copyright OptimizeRx, Inc. 2020 & 2019. All rights reserved NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("we," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor ...

NASDAQ:OPRX A Digital Health Platform Corporate Presentation Physician Communications Patient Engagement Adherence August 2020 © Copyright OptimizeRx, Inc. 2020 & 2019. All rights reserved NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("we," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor sh ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Miriam Paramore - President Conference Call Participants Ryan Daniels - William Blair Andrew D'Silva - B. Riley FBR Eric Martinuzzi - Lake Street Richard Baldry - ROTH Capital Alex Silverman - AWM Investments Josh Goldberg - G2 Investment Partners Operator Good afternoon, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

NASDAQ:OPRX A Digital Health Platform Corporate Presentation May 2020 © Copyright OptimizeRx, Inc. 2020 & 2019. All rights reserved Provider Services Patient Support Care Management NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("we," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdictio ...

OptimizeRx Corporation (NASDAQ:OPRX) Q1 2020 Earnings Conference Call May 4, 2020 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Miriam Paramore - President Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Conference Call Participants Andrew D'Silva - B. Riley FBR Richard Baldry - Roth Capital Ryan Daniels - William Blair Eric Martinuzzi - Lake Street Alex Silverman - AWM Investments Operator Good afternoon and thank you for joining us today to disc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) | Nevada | 26-1265381 | | --- | --- | | (State or other ...